RxAnte Announces Patent Issuance for Value of Future Adherence (VFA®) Score

WASHINGTON--()--RxAnte, Inc., a leading provider of predictive analytics and targeted clinical programs for medication management, announced today the issuance of US Patent No. 10,318,897 for the development of its technology to calculate the Value of Future Adherence®(VFA). Applied at the individual patient-level, the score calculates expected cost savings to health plans associated with members’ adherence to medication therapy.

The patent describes how the score, which takes into account the probability the member will be non-adherent to prescribed medication therapies combined with the likelihood of conversion to adherence, is used to accurately determine the value of intervening upon the member. RxAnte health plan clients deploy VFA to quantify cost avoidance opportunities and inform population-level outreach initiatives. For a Medicare plan of 130,000 members, VFA quantified a 2017 cost savings opportunity of more than $10M associated with improving members’ medication use.

“We devised this approach in part after studying our real-world data in which adherent members demonstrated meaningfully lower medical utilization than their non-adherent peers,” said Loren Lidsky, Chief Analytics Officer and co-founder of RxAnte. “Deploying this model into a care management setting and now seeing our pioneering work recognized in this patent issuance represents a milestone achievement for our data science and analytics teams.”

RxAnte currently manages 10M lives on behalf of national and regional health plans and continues to innovate its market-leading suite of quality improvement and cost savings solutions.

About RxAnte, Inc.

RxAnte, Inc. is dedicated to getting more from medicines. A trusted provider of advanced analytics and targeted clinical programs for health plans and servicing more than 10 million lives, the RxAnte® systems, which are HITRUST and SOC-2 certified, identify members at risk for drug therapy problems and support delivery of appropriate clinical interventions. Since 2011, this proven approach has enabled clients to improve quality measures and reduce total cost of care.

Contacts

Chris Bane, 412-228-1641

Contacts

Chris Bane, 412-228-1641